Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL

NCT07551583 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Hodgkin Lymphoma

Interventions

DRUG: Nivolumab
DRUG: Doxorubicin Hydrochloride
DRUG: Vinblastine
DRUG: Dacarbazine

Sponsor

M.D. Anderson Cancer Center